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The quality of reporting clinical and preclinical research is not optimal. Reporting guidelines can help make reports
of research more complete and transparent, thus increasing their value and making them more useful to all
readers. Getting reporting guidelines into practice is complex and expensive, and involves several stakeholders,
including prospective authors, peer reviewers, journal editors, guideline developers, and implementation scientists.
Working together will help ensure their maximum uptake and penetration. We are all responsible for helping to
ensure that all research is reported so completely that it is of value to everybody.
Please see related article: http://dx.doi.org/10.1186/s12916-015-0266-y
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There is a large body of evidence indicating the very
inadequate reporting of research, both clinical and pre-
clinical. For example, in a survey of highly cited (>500
citations) animal studies from seven leading journals
by impact factor (Science, Nature, Cell, Nature Medi-
cine, Nature Genetics, Nature Immunology, and Nature
Biotechnology) less than 20% of them described the ran-
domization processes of the animals or blinding [1]. These
findings have been consistent across preclinical research
content areas (e.g., [2,3]).
To help increase the number of published papers that
are completely and transparently reported, and thus re-
duce and/or eliminate the number of unusable publica-
tions, reporting guidelines have been developed since the
early 1990s. There has been a proliferation in their num-
bers, particularly in the last decade. Reporting guidelines
are popular; the EQUATOR Network’s library of reporting
guidelines indicates more than 200 in existence, cover-
ing a wide variety of designs, data, populations, as well* Correspondence: dmoher@ohri.ca
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unless otherwise stated.as clinical, preclinical, and other characteristics, with at
least another score in development [4]. The Network
is working to harmonize these activities and has also
published advice on how to develop reporting guide-
lines [4], thus helping to ensure their rigorous develop-
ment and usefulness. One reason for their popularity is
that, when used appropriately by prospective authors,
and endorsed and implemented optimally by journals,
they have their intended effect, namely, of improving the
completeness of research reports [5-7], thus increasing the
value of research findings to clinicians, patients, and other
interested readers.
Recently published reporting guidelines
Another reporting guideline – CoBRA, indicating how
to optimally cite bioresources – has been published in
BMC Medicine [8]. At least two other reporting guide-
lines have been published this year already [9,10]. In
2013, the National Institutes of Health entered the fray,
supported by the Nature Publishing Group and Science
magazine, and proposed the Principles and Guidelines
for Reporting Preclinical Research (NIHPG) [11] with a
meeting involving 30 journal editors [12]. This triumvirate
is an important and influential group. The NIHPG include
the better performance of statistical analysis, transparency
in reporting, data and material sharing, consideration ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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guidelines, with a focus on authors providing complete
information about the methods used in their studies to
allow interested readers to replicate them. Within a
short period of time the NIHPG have been endorsed by
an impressive, and growing, number of journals, such
as Blood, and groups, including the American Association
for Cancer Research and the World Association of
Medical Editors [13].
Reporting preclinical research: how does NIHPG
compare with existing guidelines?
In addition to the NIHPG, there are several other op-
tions [14-17] for prospective authors of preclinical re-
search to report what they did and found, including the
Animal Research: Reporting of In Vivo Experiments
(ARRIVE) [18]. ARRIVE is a reporting guideline deve-
loped in partnership with the National Centre for the
Replacement, Refinement and Reduction of Animals in
Research [19]. The guidance was rigorously developed
and followed a review of published animal studies that
provided a rationale for moving forward. The develop-
ment process also included a consensus meeting with a
broad spectrum of stakeholders interested in animal re-
search. At its core, the ARRIVE guidance is a 20-item
checklist covering what authors should report in the
Introduction, Methods, Results, and Discussion sections
of their papers. For example, item 8 asks authors to re-
port on the experimental animals used: “Provide details
of the animals used, including species, strain, sex, deve-
lopmental stage (e.g. mean or median age plus age range)
and weight”. There is evidence that authors are not pro-
viding this information [20], despite it being essential if
others are interested in replication [21].
The ARRIVE guidelines and NIHPG have different
scope but similar objectives. The NIHPG is primarily fo-
cused on journal policy; for instance, the guidance rec-
ommends that journals have either no or generous limits
on the length of their methods sections. In contrast, the
ARRIVE guidelines are focused on reporting within the
manuscript itself with its 20-item checklist, compared to
the six ‘core’ reporting items found in the NIHPG. There
is little difference between the six proposed items and
their corresponding items (sub-items) in the ARRIVE
checklist. Thus, the NIHPG items may be considered a
minimum set of reporting items that are focused on the
internal validity and statistics of a paper, whereas the
ARRIVE guidelines are comprehensive and cover the en-
tire paper from title to discussion. Indeed, the NIHPG
even recommends following community standards such
as the ARRIVE guidelines, suggesting that it is intended
to co-exist with these other standards.
While the NIHPG and ARRIVE efforts to improve the
reporting of preclinical research, are admirable, it ispossible they might be seen as confusing, particularly to
prospective authors. For example, in journals that en-
dorse both ARRIVE (also endorsed by many journals –
[22]) and NIHPG, authors might not know whether to
use the NIHPG and/or ARRIVE and may elect to use
neither, thus negating the efforts of both groups (in areas
of overlap, such as statistics, should authors choose one
guidance over another one and, if so, which one?). Indeed,
a similar situation occurred during the developing of the
CONSORT Statement for reporting randomized trials.
The CONSORT guidance was produced about 6 months
before the Asilomar guidance. Dr. Drummond Rennie,
then deputy editor of JAMA, recommended the two
groups work together to produce a single guidance thus
providing more clarity and direction for prospective
authors. Similarly, the CONSORT group wanted to in-
corporate the TIDieR guidance for describing interven-
tions [23] into the CONSORT checklist. Members of
both groups discussed how best to do this and provided
some guidance on this for prospective authors [23].
While the NIHPG guidance appears to have face valid-
ity and support, a more pressing question is whether it
will have its intended effect, namely, improving the com-
pleteness and transparency when reporting preclinical
research, as well as facilitating the likelihood of repro-
ducible studies being done. There is likely little merit in
editors asking authors to use the guidance – the inter-
vention – if it has only a minimal effect on relevant out-
comes such as better reporting and enabling others to
adequately replicate methods. Unfortunately, an assess-
ment of the benefits (and harms) of reporting guidelines
has not been a top priority of guideline developers [24],
to date. We hope the NIHPG developers will actively
plan to conduct an evaluation of their guidance and en-
courage others to do likewise. Attention to relevant out-
comes will be important to consider. Evaluations assessing
adherence to reporting guidelines (i.e., in addition to
endorsement) may provide a more meaningful insight
into its impact on completeness of reporting when used
at different stages of the editorial process. One such
recently performed evaluation [25] incorporated these
concepts by comparing the use and non-use of reporting
guidelines during peer review on author-revised manus-
cript quality.
Having produced the NIHPG – an intervention to
help improve the transparency and better reporting of
preclinical research – it is important to consider its
endorsement and implementation. More generally, are
journals using similar explicit language regarding the
endorsement of either guidance? Our experiences are
that there is a wide variability in the language of endorse-
ment and that this is confusing to prospective authors,
thus potentially reducing the intended effectiveness of the
guidance. Guideline developers are starting to provide
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standard and successful endorsement strategy [9].
Implementing reporting guidelines
While endorsement is an important step, how journals
implement reporting guidelines is a critical factor. There
is wide variability in how journals implement reporting
guidelines [26] possibly because guideline developers have
not focused on how to do this until recently [27,28]. If
editorial procedures are not consistently available on-
line it will be difficult to assess journal implementation
of NIHPG endorsement (that is, verification by the jour-
nals’ editorial team of author adherence to it). Editors may
want to develop explicit statements about their journals’
endorsement of NIHPG, and other reporting guidelines,
in their ‘Instructions to Authors’, and optimally to re-
commend submission of relevant checklists at the time of
manuscript submission. To further implementation prac-
tices, editors may also want to recommend peer reviewers
use reporting guidelines during their manuscript review
assessment [29]. Such active implementation policies by
journals will lead to more complete, clear, transparent,
and reproducible publications, ultimately increasing the
usability and value of preclinical research reports.
Well-developed reporting guidelines can improve the
reporting and usefulness of all research. If studies are re-
ported with enough detail for the findings to be imple-
mented in practice, they are more helpful to health care
providers, policy makers, and patients for making deci-
sions. Transparent reporting also allows decision makers
to judge the internal validity and applicability of the re-
search, and enables others to reproduce the findings.
Currently we do not know which reporting guidelines are
most helpful in achieving this goal because of the variabil-
ity in their development; this was a discussion theme at a
recent EQUATOR Network meeting [30]. The develop-
ment of a tool to assess the robustness (and other fea-
tures) of reporting guidelines will help all stakeholders,
particularly research funders and journal editors, to make
decisions on which reporting guidelines to focus their en-
dorsement and implementation efforts. Similarly, robust
guidelines are likely the ones for prospective authors to
spend their time using.
Getting reporting guidelines into practice is complex
and expensive, and involves many players, including pro-
spective authors, peer reviewers, journal editors, guide-
line developers, and implementation scientists. Working
together will help ensure their maximum uptake and
penetration. Technology is also likely to facilitate imple-
mentation of reporting guidelines, such as software to
help prospective authors ensure they remember to re-
port on every aspect of the research they are reporting,
and journal editors to assess the degree of compliance
to guidelines they endorse. Unfortunately, to date, therehas been very limited funding available to develop and
help maximize the potential of reporting guideline uptake.
Perhaps having the NIH involved in reporting guideline
efforts will encourage them and others to commit more
resources to these efforts. We are all responsible for help-
ing to ensure that all research is reported so completely
that it is of value to everybody.
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